Bleomycin sensitivity in patients with familial and sporadic polyposis: a pilot study

Human peripheral blood lymphocytes from 10 patients with familial adenomatous polyposis (FAP) showed a significantly higher incidence of chromatid breaks when compared to cells from 10 normal individuals, after exposure to bleomycin (BLM) during the G2 phase. However, no significant increase in bleomycin sensitivity was observed in lymphocytes from 10 patients with sporadic adenomatous polyps (AP) vs. 10 normal individuals (P = 0.67). Individuals that exhibited an average number of chromatid breaks per cell higher than 0.80 were considered sensitive to the drug. No control showed susceptibility to BLM, as compared to 3 out of 20 patients.

Saved in:
Bibliographic Details
Main Authors: Sales,Magaly M., Lucca,Edmundo J. de, Yamashita,Seizo, Saad,Luis Henrique Cury
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Genética 1999
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47571999000100004
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human peripheral blood lymphocytes from 10 patients with familial adenomatous polyposis (FAP) showed a significantly higher incidence of chromatid breaks when compared to cells from 10 normal individuals, after exposure to bleomycin (BLM) during the G2 phase. However, no significant increase in bleomycin sensitivity was observed in lymphocytes from 10 patients with sporadic adenomatous polyps (AP) vs. 10 normal individuals (P = 0.67). Individuals that exhibited an average number of chromatid breaks per cell higher than 0.80 were considered sensitive to the drug. No control showed susceptibility to BLM, as compared to 3 out of 20 patients.